The premorbid personality of patients with Parkinson’s disease.- Parkinson’s disease: development of dementia in aging.- Psychometric assessment of early signs of dementia in special consideration of Parkinson’s and Alzheimer’s disease — an update.- Sensory and musculo-skeletal dysfunction in Parkinson’s disease—premonitory and permanent.- Autonomic nervous system screening in patients with early Parkinson’s disease.- Clinical and biochemical characteristics of early depression in Parkinson’s disease.- Psychomotor investigations in depressed patients by comparison with Parkinson patients.- Quantitative analysis of voluntary and involuntary motor phenomena in Parkinson’s disease.- Motor performance test.- Measuring body movements in neurological disease, with special reference to Parkinson’s disease.- Long-term measurement of tremor: early diagnostic possibilities.- Tremor and electrically elicited long-latency reflexes in early stages of Parkinson’s disease.- Evoked potentials in Parkinson’s disease.- Brain mapping of EEG and evoked potentials during physiological aging and in Parkinson’s disease, dementia and depression.- Positron emission tomography in Parkinson’s disease glucose metabolism.- Parkinson’s disease studied using PET.- Pathobiochemistry of the extrapyramidal system: a “short note” review.- Dopaminergic neurotransmission and status of brain iron.- Dopaminergic modulation of neuropeptide gene expression in the rat striatum.- The diagnostic relevance of Lewy bodies and other inclusions in Parkinson’s disease.- Cytoskeletal pathology of the Lewy bodies.- Plasma concentrations of endogenous DOPA and 3-O-methyl-DOPA in rats administered benserazide and carbidopa alone or in combination with the reversible COMT inhibitorRo41-0960.- Catecholamines in urine, blood and cerebrospinal fluid.- 3H-spiperone binding to lymphocytes is increased in schizophrenic patients and decreased in parkinson patients.- Platelet MAO-B activity in humans and stumptail monkeys: in vivo effects of the reversible MAO-B inhibitor Ro19-6327.- Aspartate, glutamate, and glutamine in platelets of patients with Parkinson’s disease.- Hypothalamic dysfunction and neuroendocrine research in Parkinson’s disease.- The MPTP model: an update.- Histochemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson’s disease?.- Importance of dopaminergic and GABAergic neurones of the nucleus accumbens and the caudate nucleus for motoricity.- Is D-1 receptor stimulation important for the anti-parkinson activity of dopamine agonists?.- Pharmacological and clinical-pharmacological aspects of D1- and D2-receptors.- Chemical modulation of membrane-bound receptors.- Transplantation of dopamine-synthesizing cells — new therapy for Parkinson’s disease?.- L-dopa in Parkinson’s disease.- Pharmacokinetic investigations of various levodopa formulations.- Iron therapy in Parkinson’s disease. Stimulation of endogenous presynaptic L-DOPA biosynthesis by the iron compound oxyferriscorbone.- Provisional experiences with the combination of L-dopa and L-deprenyl.- Clinical pharmacology of amantadine and derivatives.- Dopamine agonist treatment in early Parkinson’s disease.- Subcutaneous apomorphine in Parkinson’s disease.- Continuous dopaminergic stimulation with parenteral lisuride in complicated Parkinson’s disease.- Discussion.
